Protagonist Therapeutics, Inc
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, 94560-1160
Mailing Address 7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, 94560-1160
Phone (510) 474-0170
Fiscal Year End 1231
EIN 980505495
Financial Overview
FY2025
$744.73M
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 10-K Annual financial report | February 25, 2026 | View on SEC |
| 8-K Current report of material events | February 25, 2026 | View on SEC |
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 10, 2026 | View on SEC |
Insider Trading
STRONG SELL 6 insiders
19 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.